ST-503
Small Fiber Neuropathy (SFN)
Phase 1/2Enrolling (STAND Study)
Key Facts
Indication
Small Fiber Neuropathy (SFN)
Phase
Phase 1/2
Status
Enrolling (STAND Study)
Company
About Sangamo Therapeutics
Sangamo Therapeutics is a public biotech company focused on translating groundbreaking zinc finger technology into genomic cures for severe diseases with high unmet need. The company has built a diversified pipeline of wholly-owned and partnered programs, primarily in neurology, with key assets in late-stage clinical development for Fabry disease and hemophilia A. Sangamo's strategy combines internal development of neurology-focused therapies with strategic collaborations with major pharmaceutical companies to expand its reach and validate its platform technology.
View full company profile